Investor Presentaiton
Rigosertib: IV or oral delivery
Published OnlineFirst February 3, 2014; DOI: 10.1158/1078-0432.CCR-13-2506
Clinical
Cancer
Research
Cancer Therapy: Clinical
Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual
Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with
Advanced Solid Malignancies
Daniel W. Bowles', Jennifer R. Diamond', Elaine T. Lam', Colin D. Weekes', David P. Astling',
Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler1, Stephen B. Keysar¹,
Elizabeth Freas, Dara L. Aisner, Chen Ren³, Aik-Chook Tan¹, Francois Wilhelm³, Manoj Maniar³,
S. Gail Eckhardt, Wells A. Messersmith', and Antonio Jimeno¹
25
Clin Cancer Res Feb 3 2014 DOI:10.1158/1078-0432.CCR-13-2506 MID:
0
ONCONOVA
THERAPEUTICSView entire presentation